Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP
Interferon beta‐1a showed no clear difference in participants who completed the study and did not restart IVIg… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
4 findings from 1 review
no estimate extracted
6 studies · 587 participants
Moderate
no estimate extracted
4 studies · 120 participants
Very low
no estimate extracted
2 studies · 467 participants
Moderate
Show 1 more finding
Death or disability after 1 year · patients with Guillain‐Barré syndrome
Corticosteroid showed no clear difference in death or disability after 1 year compared with control (moderate certainty).
1 finding from 1 review
Adverse events ‐ Diabetes mellitus requiring insulin · patients with Guillain‐Barré syndrome
Corticosteroid leads to higher adverse events ‐ diabetes mellitus requiring insulin compared with control (high certainty).
1 finding from 1 review
Adverse events: hypertension · patients with Guillain‐Barré syndrome
Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).
1 finding from 1 review
Change in muscle strength ‐ QMT leg score (lb) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Muscle strength · patients with Duchenne muscular dystrophy
2 findings from 1 review
Change in 10‐metre walking time · patients with Duchenne muscular dystrophy
1 finding from 1 review
Change in 4‐stair climbing time · patients with Duchenne muscular dystrophy
1 finding from 1 review
Body‐mass index (BMI) · patients with Duchenne muscular dystrophy
1 finding from 1 review